Don't miss

Retrophin, Inc. (RTRX)

By on March 20, 2013

retrophinRetrophin, Inc. (OTCQB: RTRX) is a publicly-traded New York-based biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases.

Company Data

Industry: BioTech

IR Contact: Martin Shkreli CEO

IR Email: [email protected]

Phone: (212) 983-1310

Address: Retrophin, Inc.
777 Third Avenue, 22nd Floor
New York, NY 10017

Fiscal Year End: December, 31st

Executives: Martin Shkreli – President and CEO

Online Resources

Company Website:

Stock Information:

Company Fillings

Company Presentation

If you can’t view the report click here to download

You must be logged in to post a comment Login